The urokinase receptor: Structure, regulation and inhibitor-mediated internalization

Fibrinolysis and Proteolysis

Volumn 8, Issue SUPPL. 1, 1994, Pages 182-188

  Blasi, F ^a   Conese, M ^a   Moller L B ^b   Pedersen, N ^c   Cavallaro, U ^a   Cubellis, M V ^a   Fazioli, F ^a   Hemandez Marrero, L ^a   Limongi, P ^a   Munoz Canoves, P ^a   Resnati, M ^a   Riittinen, L ^a   Sidenius, N ^a   Soravia, E ^a   Soria, M R ^a   Stoppelli, M P ^a   Talarico, D ^a   Teesalu, T ^a   Valcamonica, S ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b AS   (Italy)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE; UROKINASE RECEPTOR;

CELL SURFACE; CONFERENCE PAPER; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING;

EID: 0028087747     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/0268-9499(94)90716-1     Document Type: Article

References (88)

1. A cellular binding site for the Mr 55,000 form of the human plasminogen activator urokinase
2. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase to a specific receptor on U937 monocytes
3. Urokinase-type plasminogen activator and its receptor: new target for anti-metastatic therapy?
4. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-? to TGF-?
5. Antibodies to plasminogen activator inhibit human tumor metastasis
6. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade
7. Modulation of the metastatic potential by cell surface urokinase of murine cells
8. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo
9. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface bound urokinase
10. Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras transformed NIH3T3 cells
11. Examination of the role of the urokinase receptor in humoan colon cancer mediated laminin degradation
12. Mouse L cells expressing prourokinasetype plasminogen activator: effects on extracellular matrix degradation and invasion
13. Plasminogen activator inhibitor type I is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells
14. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse
15. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells
16. Prevention of metastasis by inhibition of the urokinase receptor.
17. Receptor for urokinase is present in tumorassociated macrophages in ductal breast carcinoma
18. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2
19. Urokinase-type plasminogen activator (uPA) antigen is a predictor of eartly relapse in breast cancer
20. Urokinase-type plasminogen activator a new and independent prognostic marker in breast cancer
21. Biological and clinical relevance of the urokinase-type plasminogen activator in breast cancer
22. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinoma are associated with poor prognosis
23. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma
24. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue
25. Cloning and expression of the receptor for human urokinase plasminogen activator a central molecule in cell-surface plasmin-dependent proteolysis
26. Structural requirements for glycosyl-phosphatidylinositol-anchor attachment in the cellular receptor for urokinase plasminogen activator
27. Cellular receptor for urokinase plasminogen activator: carboxy terminal processing and membrane anchoring
28. The ligand-binding domain of the cell surface receptor for urokinase plasminogen activator
29. Localization of the disulfide bonds for human urokinase-type plasminogen activator receptor. A domain structure belonging to a novel superfamily of glycolipid anchored membrane proteins
30. A soluble ligand binding mutant of the human urokinase plasminogen activator receptor
31. N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand.
32. Regulation of urokinase receptors in monocyte-like U937 cells by phorbol ester phorbol-myristate acetate
33. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes
34. Accessibility of receptor-bound urokinase to type- I plasminogen activator inhibitor
35. Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors
36. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1
37. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
38. Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells
39. Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor.
40. Internalization of the urokinase:plasminogen acftivator inhibitor type-1 complex is mediated by the urokinase receptor
41. The receptor-binding sequence of urokinase
42. Characterization of the cellular binding site for urokinase plasminogen activator
43. Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator:plas minogen activator inhibitor type I complexes
44. Sequence identity between the a2macroglobulin receptor and low density lipoprotein receptor related protein suggests that this molecule is a multifunctional receptor
45. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins
46. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds lipoprotein lipase and beta-migrating very low density lipoprotein associated with the lipase.
47. Low density lipoprotein receptor-related protein/α2 macroglobulin receptor mediates cellular uptake of pro-urokinase
48. Surface location and high affinity for calcium of a 500 kd liver membrane protein closely related to the LDL receptor suggest a physiological role as lipoprotein receptor
49. Proteolytic processing of the 600 kD low density lipoprotein receptor-related protein (LRP) occurs in a trans-Golgi compartment
50. Primary structure of the a2-macroglobulin receptor-associated protein. Human homo logue of a Heymann nephritis antigen
51. Analysis of ligand recognition by the purified a2-macroglobulin receptor (low density lipoprotein receptor-related protein). Evidence that high affinity of α2-macroglobulin proteinase complex is achieved by binding to adjacent receptors
52. A novel mechanism controlling the activity of α2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39 kDa receptor associated protein
53. LDL receptor-related protein internalizes and degrades uPA-PAI-I and is essential for embryo implantation
54. Receptor mediated binding of the fibrinolytic components plasminogen and urokinase to peripheral blood cells
55. Urokinase receptor. An activation antigen in human T lymphocytes
56. Bacterial liposaccharide phorbol myristate acetate and muramyl dipeptide stimulate the expression of a human monocyte surface antigen Mo3e
57. Phorbol ester induces the biosynthesis of glycosylated and non-glycosylated plasminogen activator inhibitor 2 in high excess over urokinasetype plasminogen activator in human U937 lymphoma cells
58. Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells
59. An autocrine role for urokinase in phorbol-ester mediated differentiation of myeloid cell lines
60. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors
61. A conjugate between human urokinase and saporin a type-1 ribosome-inactivating protein is selectively cytotoxic to urokinase receptorexpressing cells
62. Phosphatidylinositol membrane anchors and T-cell activation
63. An aminoterminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoclast-like cells
64. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.
65. Growth factor-like effect of urokinase type plasminogen activator in human renal cells
66. Structural requirements for the growth factor activity of the amino terminal domain of urokinase
67. GPI-anchored cell-surface molecules complexed to protein tyrosine kinases
68. Phosphatidylinositol membrane anchors and T-cell activation
69. Association of the CD59 and CD55 cell surface glycoproteins with other membrane molecules
70. The nature of large non-covalent complexes containing glycosyl-phosphatidylinositol-anchored membrane glycoprotein and protein tyrosine kinases
71. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanisms for signal transduction in human epithelial cells
72. Interaction of urokinase-type plasminogen activator (uPA) with its cellular receptor (uPAR) induces phosphorylation of a 38 kDa protein
73. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth beta-I-like molecule by plasmin during co-culture
74. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system
75. Transforming growth factor beta is a strong and fast acting positive regulator of the level of type I plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts
76. Cell density dependent effects of TGF-βI demonstrated by plasminogen activator-based assay of TGF-β
77. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement plasminogen activator synthesis and DNA synthesis
78. Phorbol ester induces cells to invade a fibrin matrix in the presence of fibrinolytic inhibitors
79. Increased proteolytic activity is responsible for the aberrant morphogenetic behaviour of endothelial cells expressing middle T oncogene
80. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity
81. Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells
82. Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells
83. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization
84. Physiological consequences of loss of plasminogen activator gene function in mice